Jakafi® (ruxolitinib) – New indication
September 22, 2021 - Incyte announced the FDA approval of Jakafi (ruxolitinib), for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older..
Download PDF
